Trial · NCT07893509
Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)
NCT07893509, Not yet recruiting, Bladder Cancer Advocacy Network
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC). Trials, record NCT07893509. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893509
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)
- NCT number
- NCT07893509
- Status
- Not yet recruiting
- Enrollment
- 1,400 participants, estimated
- Lead sponsor
- Bladder Cancer Advocacy Network
- Conditions
- NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
- Interventions
- This is a non-interventional, observational, prospective study.
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Arms I-IV: Overall Mortality at 2 years. | 36 months | Kaplan-Meier analysis for recurrence-free and progression free survival at 3, 6, 12, 18, 24, and 36 months. |
| Primary | Arm V: MIBC patients (Va adjuvant observation and Vb adjuvant therapy) | 36 months | The primary outcome is to demonstrate the association of ctDNA and disease free state (DFS longitudinally ) |
| Secondary | Arms I-IV Secondary Outcomes | 36 months | For patients with NMIBC, secondary outcomes include patient-reported health-related quality of life, decision-making for patients and providers, cancer outcomes and treatment choices for difference disease stages. |
| Secondary | Arm V Secondary Outcomes | 3 years | For MIBC, to demonstrate the association of NAT-driven ctDNA clearance with pathologic response. |
| Secondary | Arm V: MIBC Cohort Va Secondary Measures | 3 months | For MIBC patients in Cohort Va, to demonstrate the association of post-RC ctDNA status (positive vs. negative at 3 months post-CX point) with disease-free survival |
| Secondary | Arm V: MIBC Cohort Vb Secondary Outcomes | 3 years | For MIBC patients in Cohort Vb, to demonstrate the association of baseline ctDNA status (positive vs negative) with disease-free survival (DFS). For Cohort Vb, association of longitudinal ctDNA dynamics post-definitive therapy with DFS. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893509
GET https://conductscience.org/api/trials/v1/NCT07893509/registered